Alexandre Esadze received his Ph.D. degree in 2014 through our Structural Biology / Biophysics graduate program track at UTMB. He is currently working as a Principal Scientist at Pfizer, Inc.
During his Ph.D. study at UTMB, Alex conducted biophysical studies of protein-DNA interactions in the laboratory of Prof. Junji Iwahara. Using NMR spectroscopy, stopped-flow fluorescence, and other biophysical methods, Alex investigated how a zinc-finger
transcription factor Egr-1 scans DNA and locates its target sequence among numerous different sequences. Alex published many research articles in prestigious journals such as JACS, Nucleic Acids Research, and PNAS. After completing his research at
UTMB, Alex received a postdoctoral training in the laboratory of Prof. James Stivers at Johns Hopkins University. There, Alex studied how DNA-repair enzymes scan genomic DNA in the nuclei. His work was supported by a fellowship from the American Heart
Association.
In 2019, Alex joined Pfizer as a Senior Scientist. With his biophysical expertise, Alex characterizes antibody-antigen interactions related to COVID-19, Lyme disease, and other diseases as part of vaccine R&D at Pfizer. In 2022, Alex was promoted
to the rank of Principal Scientist. His current career in the pharmaceutical company is taking full advantage of the expertise developed through our Structural Biology / Biophysics graduate program track at UTMB.
To learn more about Alex’s career, visit his Linked-In webpage.